Proactive Investors - Run By Investors For Investors

Unnamed pharma giant to trial Midatech’s Q-Sphera drug delivery technology

Results from a study of Midatech’s acromegaly and carcinoid cancer drug, MTD201, earlier in the year showed that Q-Sphera works as planned
scientist in lab
Q-Sphera allows drugs to be delivered into the body over a prolonged period of time

A “leading global pharmaceutical corporation” has signed a deal with Midatech Pharma Plc (LON:MTPH) that will see it evaluate the latter’s Q-Sphera drug delivery platform.

Q-Sphera allows drug compounds to be released into the body in a “highly controlled manner” over a prolonged period of time; potentially from a few days to up to six months.

Under the collaboration agreement, the unnamed partner will conduct a feasibility program using the Q-Sphera technology. No financial terms have been disclosed.

READ: Midatech delighted with first-in-human data for MTD201

A study of Midatech’s MTD201 acromegaly treatment earlier this year provided a major validation of the platform, with results showing two things: that MTD201 was possibly a better treatment than rival one developed by Novartis but also that Q-Sphera works.

“We are delighted to announce this partnership with a leading global pharmaceutical corporation,” said chief executive Craig Cook.

“This marks another important step in the development of our impressive Q-Sphera technology, after the positive clinical 'proof of concept' first-in-human study earlier this year in carcinoid cancer and acromegaly.”

He added: “Together with partnerships such as the one being announced we are focused on increasing our traction in the sustained delivery market, where we hope to establish Q-Sphera as the leading platform.”

View full MTPH profile View Profile

Midatech Pharma PLC Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
skin
Wed
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use